Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Tatoud

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
BMJ (Clinical Research Ed.)|September 20, 2013
Testing times for HIVJonathan Weber, Roger Tatoud
AIDS (London, England)|November 3, 2010
Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmissionJonathan Weber, Roger Tatoud, Sarah Fidler
Journal of the International AIDS Society|November 22, 2021
A transformed global enterprise for an HIV vaccineRoger Tatoud, William Snow, José Esparza
Plos One|February 3, 2015
Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigenMaria L Knudsen, Karl Ljungberg, Roger Tatoud, et al.
Journal of Virus Eradication|April 1, 2024
Advancing HIV cure research in low- and middle-income countries requires empowerment of the next generation of scientistsRoger Tatoud, R Brad Jones, Krista Dong, et al.
Molecular Pharmacology|December 26, 2001
Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signalingDouglas J A Adamson, David Frew, Roger Tatoud, et al.
Vaccines|May 27, 2023
Experimental Medicine for HIV Vaccine Research and DevelopmentHolly Prudden, Roger Tatoud, Cathy Slack, et al.
Journal of Experimental Therapeutics & Oncology|April 23, 2005
The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasisManit Arya, Hitendra R H Patel, Claire McGurk, et al.
AIDS Research and Human Retroviruses|July 1, 2023
Perspectives on Design Approaches for HIV Prevention Efficacy TrialsHolly J Prudden, Roger Tatoud, Holly Janes, et al.
PLOS Global Public Health|April 10, 2025
Improving the efficiency of the regulatory approvals of HIV in vitro diagnostics in low- and middle-income countries: Perspective of the IAS Industry Liaison Forum diagnostic partnersTammy Steuerwald, Duncan Blair, Elliot Cowan, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
BMJ (Clinical Research Ed.)|September 20, 2013
Testing times for HIVJonathan Weber, Roger Tatoud
AIDS (London, England)|November 3, 2010
Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmissionJonathan Weber, Roger Tatoud, Sarah Fidler
Journal of the International AIDS Society|November 22, 2021
A transformed global enterprise for an HIV vaccineRoger Tatoud, William Snow, José Esparza
Plos One|February 3, 2015
Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigenMaria L Knudsen, Karl Ljungberg, Roger Tatoud, et al.
Journal of Virus Eradication|April 1, 2024
Advancing HIV cure research in low- and middle-income countries requires empowerment of the next generation of scientistsRoger Tatoud, R Brad Jones, Krista Dong, et al.
Molecular Pharmacology|December 26, 2001
Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signalingDouglas J A Adamson, David Frew, Roger Tatoud, et al.
Vaccines|May 27, 2023
Experimental Medicine for HIV Vaccine Research and DevelopmentHolly Prudden, Roger Tatoud, Cathy Slack, et al.
Journal of Experimental Therapeutics & Oncology|April 23, 2005
The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasisManit Arya, Hitendra R H Patel, Claire McGurk, et al.
AIDS Research and Human Retroviruses|July 1, 2023
Perspectives on Design Approaches for HIV Prevention Efficacy TrialsHolly J Prudden, Roger Tatoud, Holly Janes, et al.
PLOS Global Public Health|April 10, 2025
Improving the efficiency of the regulatory approvals of HIV in vitro diagnostics in low- and middle-income countries: Perspective of the IAS Industry Liaison Forum diagnostic partnersTammy Steuerwald, Duncan Blair, Elliot Cowan, et al.
Pageof 3